BioScience Managers Limited

Acrux Limited is a pharmaceutical company based in West Melbourne, Australia, specializing in the development and commercialization of generic and specialty topical pharmaceuticals. Founded in 1998, Acrux focuses on innovative drug delivery systems that administer medications through the skin. Its product offerings include testosterone solutions for men with low testosterone levels, as well as estradiol sprays for women experiencing menopausal flushes, marketed under the Evamist and Lenzetto brand names. Acrux is advancing a diverse product pipeline aimed at treating hormonal deficiencies, pain, central nervous system disorders, and contraceptive needs. The company has completed numerous human clinical trials with its lead product, Evamist, nearing the end of a phase 3 trial in the United States. With a global presence across Australia, the United States, Germany, and other countries, Acrux aims to provide affordable and effective pharmaceutical solutions through its robust technical and clinical expertise.

Cynata Therapeutics Limited is an Australian company focused on developing and commercializing its proprietary Cymerus™ mesenchymal stem cell technology for therapeutic applications. The company’s lead product candidate, CYP-001, has completed Phase I clinical trials aimed at treating graft versus host disease. In addition to this, Cynata is exploring treatments for various conditions such as asthma, heart attack, diabetic wounds, coronary artery disease, and acute respiratory distress syndrome, among others, which are currently in preclinical stages. The Cymerus technology utilizes induced pluripotent stem cells (iPSCs) derived from adult donors, enabling the efficient and scalable production of mesenchymal stem cells. This innovative approach addresses existing limitations in stem cell manufacturing, allowing for virtually limitless quantities of therapeutic cells without the need for continuous donor sourcing. Cynata collaborates with several prestigious institutions, including Monash University and Massachusetts General Hospital, to advance its research and development efforts. Founded in 2011 and based in Carlton, Australia, Cynata is positioned to significantly contribute to the field of regenerative medicine.

Adherium develops digital health technologies to improve medication adherence in chronic diseases worldwide. It offers Hailie, an asthma and COPD medication tracker comprising Bluetooth sensors for inhalers and a smartphone app for patients, caregivers, and healthcare professionals.

We are a North American company, whose mission is to provide high quality medications for those patients who need them to treat their disease by making the medicine accessible to everyone. Our reason for being is to close the gap between pharmaceutical manufacturers and patients around the world whose quality of life depends on receiving the right treatment at the right place and time. At Pharmaxis Group we believe that working closely with our customers, employees, shareholders and key partners allows us to provide exceptional value in all the services we provide. Specialized in the supply of drugs that are difficult to find in the fields of oncological, immunological, orphan diseases among others. Our global network of pharmaceutical suppliers, combined with our strong logistics network, includes certified partners in good storage and handling practices, and good manufacturing practices, all necessary to properly guarantee high quality in all the products and services.

Founded in 2013, Canary Medical specializes in developing implantable sensor technology for remote patient monitoring. Its flagship product, canturio™te, is the world's first 'smart knee' tibial extension that monitors joint performance and transmits data to the cloud autonomously.

Immunosis is a biotech company focused on advancing genetic technologies for the early detection of Primary Immune Deficiency (PID). The company has developed a proprietary diagnostic test that utilizes genetic information to identify patients with PID, aiming to shorten the time needed for diagnosis. By facilitating timely care, Immunosis seeks to improve patient outcomes for individuals suffering from immune deficiency conditions, ultimately enhancing their recovery prospects.

Rex Bionics specializes in developing robotic medical devices for rehabilitation. Its flagship product is REX, a hands-free robotic device designed to assist individuals with mobility impairments in exercising, walking, and standing. Established in 2007, the company operates out of Auckland, New Zealand.

Rex Bionics specializes in developing robotic medical devices for rehabilitation. Its flagship product is REX, a hands-free robotic device designed to assist individuals with mobility impairments in exercising, walking, and standing. Established in 2007, the company operates out of Auckland, New Zealand.

AVITA Medical is a commercial-stage regenerative medicine company focused on treating burns, wounds, and related dermatologic conditions with autologous skin cell therapies. It develops and markets a device-driven system that converts a small sample of a patient’s skin into a suspension of spray-on skin cells, enabling clinicians to treat acute burns without traditional skin grafts. The lead product, the RECELL System, prepares autologous skin cells for use in burn care and soft-tissue reconstruction, with ongoing exploration in chronic wounds, dermatology, and aesthetic indications such as vitiligo. The company operates in the United States, Australia, and the United Kingdom and maintains research collaborations to advance spray-on skin approaches for conditions like epidermolysis bullosa and skin rejuvenation. Headquartered in Valencia, California, AVITA Medical focuses on delivering regenerative skin therapies to burn centers and related clinical settings.

Saluda Medical is a medical device company specializing in closed-loop neuromodulation therapies for chronic neurological conditions. Founded in 2010 and headquartered in Australia, the company develops innovative devices like Evoke, designed to optimize neural stimulation based on real-time feedback.

HeartWare International, Inc. specializes in the development and manufacturing of small implantable heart pumps, also known as ventricular assist devices, aimed at treating advanced heart failure. The company offers the HeartWare Ventricular Assist System, which comprises a left ventricular assist device, patient accessories, and surgical tools designed to provide critical circulatory support for patients in the advanced stages of heart failure. Additionally, HeartWare is working on the Miniaturized Ventricular Assist Device, intended for chronic heart failure patients. The company markets its products through clinical studies in the United States and directly to cardiac centers and hospitals worldwide. Headquartered in Framingham, Massachusetts, HeartWare is committed to improving the quality of life for patients suffering from severe heart conditions.

Bionomics is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for central nervous system disorders and cancer in Australia and the United States. Its lead program, BNC210, is a selective negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor studied for anxiety, panic, agitation, and post-traumatic stress disorder. The company’s portfolio also includes BNC105, a vascular disrupting agent for solid tumors; BNC101, a monoclonal antibody targeting cancer stem cells; and BNC375, a compound aimed at cognitive impairment in Alzheimer's disease. Bionomics also develops ionX, a genomics platform that supports its drug discovery efforts, and maintains strategic partnerships with industry collaborators to advance its therapies.

Peplin is a development-stage specialty pharmaceutical company dedicated to advancing medical dermatology products. The company focuses on PEP005, a compound derived from Euphorbia peplus, which is utilized in its lead product, a patient-applied topical gel currently in Phase III clinical trials for the treatment of actinic keratosis. Additionally, Peplin is developing a physician-applied topical gel for superficial basal cell carcinoma, also based on PEP005. The active ingredient in both products is a small molecule extracted and purified from the sap of Euphorbia peplus. Peplin's commitment to addressing skin disorders is further underscored by its acquisition of Neosil, Inc., a dermatology-focused company, before eventually being acquired by LEO Pharma A/S.

Arana Therapeutics is a biopharmaceutical company based in Macquarie Park, Australia, focused on developing antibody- and peptide-based therapies for inflammatory diseases and cancer.

Acrux Limited is a pharmaceutical company based in West Melbourne, Australia, specializing in the development and commercialization of generic and specialty topical pharmaceuticals. Founded in 1998, Acrux focuses on innovative drug delivery systems that administer medications through the skin. Its product offerings include testosterone solutions for men with low testosterone levels, as well as estradiol sprays for women experiencing menopausal flushes, marketed under the Evamist and Lenzetto brand names. Acrux is advancing a diverse product pipeline aimed at treating hormonal deficiencies, pain, central nervous system disorders, and contraceptive needs. The company has completed numerous human clinical trials with its lead product, Evamist, nearing the end of a phase 3 trial in the United States. With a global presence across Australia, the United States, Germany, and other countries, Acrux aims to provide affordable and effective pharmaceutical solutions through its robust technical and clinical expertise.

Nexvet Australia Pty Ltd is a biopharmaceutical company based in Melbourne, Australia, specializing in the development of biological therapies for companion animals. Founded in 2010, Nexvet focuses on creating species-specific monoclonal antibodies to address chronic pain, immune oncology, chronic inflammation, and allergies in pets. The company's key products include Ranevetmab and Frunevetmab, which target nerve growth factor to alleviate pain associated with osteoarthritis in dogs and degenerative joint disease in cats, respectively. Additionally, Nexvet is developing NV-03, a monoclonal antibody for chronic joint pain in horses. Utilizing a unique technology called PETisation, Nexvet customizes therapies to specific species, enhancing the effectiveness and safety of treatments while minimizing immune responses. As a subsidiary of Zoetis Inc., Nexvet aims to transform animal medicine by collaborating with global partners in veterinary and human health to advance its innovative pipeline.

AmpliPhi Biosciences is a biopharmaceutical company that specializes in developing bacteriophage-based therapies for bacterial infections. By utilizing naturally occurring viruses known as bacteriophages, the company aims to address various bacterial infections, particularly those caused by drug-resistant strains prevalent in hospital environments. AmpliPhi has established a drug development and manufacturing platform that enables the rapid creation and production of multiple phage-based therapies. The company’s initial focus is on treating acute and chronic infections affecting the lungs, sinuses, and gastrointestinal tract. With operations in Richmond, Virginia, Colworth Science Park near London, and outside Sydney, Australia, AmpliPhi is committed to advancing its pipeline of phage therapies to effectively combat targeted bacterial diseases.

Alchemia Limited is an Australian biopharmaceutical company that specializes in developing innovative therapies. It has an FDA-approved drug, Fondaparinux sodium, and a late-stage oncology product pipeline based on its proprietary HyACT platform. Additionally, the company leverages its chemistry expertise through its drug discovery platform, VAST®, to advance its portfolio of therapeutic candidates. Alchemia's focus on biopharmaceuticals positions it at the forefront of medical innovation, aiming to address significant healthcare needs through its research and development efforts.

Adherium develops digital health technologies to improve medication adherence in chronic diseases worldwide. It offers Hailie, an asthma and COPD medication tracker comprising Bluetooth sensors for inhalers and a smartphone app for patients, caregivers, and healthcare professionals.

SeaDragon Limited is a New Zealand-based manufacturer and marketer of refined fish oils and marine bioactive compounds. The company processes fish oils and blends Omega-3 products for global health-supplement manufacturers, serving customers domestically and internationally. Based in Nelson, it focuses on producing high-purity oils derived from marine sources and supplying refined oils for nutraceutical and related applications. Established in 1986, SeaDragon operates across New Zealand and international markets.

AVITA Medical is a commercial-stage regenerative medicine company focused on treating burns, wounds, and related dermatologic conditions with autologous skin cell therapies. It develops and markets a device-driven system that converts a small sample of a patient’s skin into a suspension of spray-on skin cells, enabling clinicians to treat acute burns without traditional skin grafts. The lead product, the RECELL System, prepares autologous skin cells for use in burn care and soft-tissue reconstruction, with ongoing exploration in chronic wounds, dermatology, and aesthetic indications such as vitiligo. The company operates in the United States, Australia, and the United Kingdom and maintains research collaborations to advance spray-on skin approaches for conditions like epidermolysis bullosa and skin rejuvenation. Headquartered in Valencia, California, AVITA Medical focuses on delivering regenerative skin therapies to burn centers and related clinical settings.

Millenium Biologix Corporation is a biomedical company based in Kingston, Canada, operating primarily in the United States and Europe. Founded in 1986, the company specializes in the development and commercialization of implantable medical devices and products aimed at skeletal tissue regeneration for orthopedic applications. Among its offerings is Skelite, a synthetic bone graft designed for healing and replacement purposes. Additionally, Millenium Biologix develops Primacoll and Peptos, which are intended to stimulate bone tissue growth. The company also provides ACTES, a cell culture and tissue engineering system that automates the biological processes involved in tissue engineering.

Millenium Biologix Corporation is a biomedical company based in Kingston, Canada, operating primarily in the United States and Europe. Founded in 1986, the company specializes in the development and commercialization of implantable medical devices and products aimed at skeletal tissue regeneration for orthopedic applications. Among its offerings is Skelite, a synthetic bone graft designed for healing and replacement purposes. Additionally, Millenium Biologix develops Primacoll and Peptos, which are intended to stimulate bone tissue growth. The company also provides ACTES, a cell culture and tissue engineering system that automates the biological processes involved in tissue engineering.